Led by the Duke Clinical Research Institute and published Jan.
What does DCRI stand for?
DCRI stands for Duke Clinical Research Institute
This definition appears very frequently and is found in the following Acronym Finder categories:
- Organizations, NGOs, schools, universities, etc.
See other definitions of DCRI
We have 5 other meanings of DCRI in our Acronym Attic
- Desert Canyon Rehabilitation Hospital (Las Vegas, NV)
- Développement Créativité Ressources Humaines (French: Human Resources Creativity Development)
- Delaware County Rural Healthcare Alliance (Hamden, NY)
- Dukes County Regional Housing Authority (Vineyard Haven, MA)
- Del Condominium Rentals Incorporated (Toronto, ON, Canada)
- Dental & Cosmetic Research Institute (India)
- Department of Clinical Research Informatics (US NIH Clinical Center)
- Direction Centrale du Renseignement Intérieur
- Direction de la Coopération et des Relations Internationales (French: Directorate of Cooperation and International Relations)
- Diversified Corporate Resources, Inc.
- Disclosure of Criminal Record Information Form (UK)
- Distributed Customer Records Information System
- Diversity and Community Relations Judiciary (UK)
- Department of Corrections and Rehabilitation Juvenile Justice (California)
- Democratic Confederal Republic of Koryo (Korea)
- Dry Chemical Recharge Kit
- Digital Consumer Right-To-Know Act
- Distributed Computing Research Lab
- Data Cluster-Based Reliability Model
- Derivatives Counterparty Risk Management (UK)
Samples in periodicals archive:
The roundtable discussion was moderated by Harvey Schmitt, CEO of the Greater Raleigh Chamber of Commerce, and executives from Red Hat, the City of Raleigh, Duke Clinical Research Institute, Pentair Water Pool and Spa, and Martin Marietta Materials joined Mr.
Peterson of the Duke Clinical Research Institute in Durham, N.
Robert Harrington, MD, Professor of Medicine and Director of Cardiovascular Clinical Trials at Duke Clinical Research Institute and Dr.
and director of the Duke Clinical Research Institute.
It shows us that we can potentially refine the use of IIb/IIIa inhibitors and direct them to the patients who can really benefit from them," indicates the study's lead investigator, Robert Harrington of the Duke Clinical Research Institute.